A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies.
Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G.
Bradbury PA, et al. Among authors: miller dp.
Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):204-11. doi: 10.1158/1055-9965.EPI-07-0470.
Cancer Epidemiol Biomarkers Prev. 2008.
PMID: 18199725
Clinical Trial.